Acotec Scientific Holdings Limited SUCCESSFULLY LISTED ON HKEX
Latest Update:
24 th August, 2021

On August 24, 2021, the Chinese and global involvement in the ranks of the medical device market industry leader - Acotec Scientific Holdings Limited. ("Acotec "or the" company ", together with its subsidiaries, generally referred to as the "group", stock code: 6669. HK), today in the stock exchange of Hong Kong limited (" the Hong Kong stock exchange "), the main board listing.

 

Acotec is a leading innovative medical device company in China, providing a variety of vascular disease treatment solutions based on the concept of intervention-free implantation. The company has developed a number of world-leading interventional medical devices, especially in the drug-coated balloon (DCB) and thrombus aspiration catheters. In 2016, the company developed and launched the first peripheral DCB product in China, about four years ahead of the second similar product, and in terms of revenue generated in 2020, the company's first peripheral DCB product dominates the Chinese peripheral DCB market with approximately 86.9% of the market share. For the three months ended 2019 and 2020, and for the three months ended March 31, 2021, the group generated revenue from product sales of RMB 124.9 million, RMB 194.0 million, RMB 19.6 million and RMB 53.3 million, respectively

 

As the financial and public relations consultant team of the company, Porda Havas has been fully involved in the maintenance of domestic and foreign media relations, the design and production of listing publicity materials, and the holding of listing celebration activities during the process of the company's listing, which helped the company to successfully go public in Hong Kong.

 

The global offering of 68,633,000 shares was priced at HK $23.80 per share and the net proceeds from the global offering are expected to be approximately HK $1,529 million (assuming that the overallotment is not exercised). The initial offer of shares in the Hong Kong Public Offer was well oversubscribed, which is approximately 654.51 times the initial offer of 6,864,000 shares in the Hong Kong Public Offer; The international offering was oversubscribed by approximately 4.86 times the total number of shares available under the initial international offering.

Ms. Jing Li, Executive Director, Founder, CHIEF Executive Officer and Chairman of The Board of Acotec Scientific Holdings Limited, said, "Today's listing on the Stock Exchange marks an important milestone for Acotec, which is a leading Innovative Chinese medical device company. Has long been a mission is to become the world's leading, can provide a full set of "intervention no implant" solution for vascular disease intervention equipment provider. In the future, we will further strengthen our leading position in the DCB market; late rapid advance in clinical research product development and commercialization, strengthen the research and development capabilities, to expand manufacturing capacity; expanding geographical coverage and global strategic layout, Strive to be the best in the world."

 

 About Acotec Scientific Holdings Limited 

 

Acotec Scientific Holdings Limited  is a Chinese innovative medical device company with the concept of "intervention without implantation", providing a variety of vascular disease treatment solutions. The company has developed a number of world-leading interventional medical devices, especially in the drug-coated balloon (DCB) and thrombus aspiration catheters. We are committed to becoming the world's leading provider of interventional devices for vascular diseases, providing a complete set of "intervention without implantation" solutions. Since its inception, Shenreda has developed two core products, a unique technology platform built by four core technologies, and a comprehensive product line covering five therapeutic areas. As of August 3, 2021, the company had a total of 24 products under development, 17 of which are expected to be approved by the end of 2023.

Latest Update:
24 th August, 2021